Shape Therapeutics Revenue and Competitors

Seattle, WA USA

Location

#8709

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Shape Therapeutics's estimated annual revenue is currently $34.5M per year.(i)
  • Shape Therapeutics's estimated revenue per employee is $193,750
  • Shape Therapeutics's total funding is $148M.

Employee Data

  • Shape Therapeutics has 178 Employees.(i)
  • Shape Therapeutics grew their employee count by 23% last year.

Shape Therapeutics's People

NameTitleEmail/Phone
1
Co-FOUNDER - Chairman SABReveal Email/Phone
2
Co-FounderReveal Email/Phone
3
EVP, Preclinical DevelopmentReveal Email/Phone
4
VP, Head Process and Product DevelopmentReveal Email/Phone
5
VP, People OperationsReveal Email/Phone
6
General CounselReveal Email/Phone
7
VP FinanceReveal Email/Phone
8
Associate DirectorReveal Email/Phone
9
Senior Director, Head Pipeline ResearchReveal Email/Phone
10
Chief Scientific OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.9M60%N/AN/A
#2
$0.9M60%N/AN/A
#3
$5.1M336%N/AN/A
#4
$5.7M3742%N/AN/A
#5
$1.4M18-10%N/AN/A
#6
$3.7M48-21%$16MN/A
#7
$1.1M70%N/AN/A
#8
$0.8M5-81%N/AN/A
#9
$2.5M16-27%N/AN/A
#10
$0.8M5-17%N/AN/A
Add Company

What Is Shape Therapeutics?

Shape Therapeutics (ShapeTx) is a development-stage biotechnology company establishing itself as the leader in next-generation gene therapy. Our novel technology platform enables direct in vivo targeting/modification of RNA by leveraging ADARs (Adenosine Deaminase Acting on RNA), suppressor tRNAs, and immune-stealth adeno-associated viruses (AAVs). ShapeTx is providing solutions to many of the challenges that contemporary genome engineering technologies face (like CRISPR, TALENs, etc.), such as permanent off-target damage, high risk of immunogenicity and therefore low in vivo applicability as effective gene therapy approaches. ShapeTxᅢᄁ¬ツᆲ¬トᄁs technology instead engages natural human cellular machinery to target RNA with high in vivo efficiency. Shape Genome, Shape Life!

keywords:N/A

$148M

Total Funding

178

Number of Employees

$34.5M

Revenue (est)

23%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Shape Therapeutics News

2022-04-19 - Global Peptide Therapeutics Market USD 75 Billion Opportunity

Global Peptide Therapeutics Market & Clinical Trials Insight 2028 ... is determined by the amino acid sequences and shape of the peptides.

2022-04-17 - BioMed Realty Buys Seattle’s Denny Park South

... Novo Nordisk, Omeros Corporation, InBios International, Inc., Lyell Immunopharma, Inc., Shape Therapeutics and Tableau.

2021-07-16 - Shape Therapeutics picks up $112M

Shape Therapeutics has raised $112 million in a Series B co-led by Decheng Capital and Breton Capital. The Seattle-based company is a developer of RNA targeting, editing and replacement technologies intended to treat neurodegenerative disorders and rare genetic diseases. Shape Therapeutics was v ...

2021-07-15 - Shape Therapeutics Secures $112 Million in Series B Financing to Advance Breakthrough RNA Technology Platforms to Democratize Gene Therapy

SEATTLE, July 15, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the completion of a $112 million Series B financing round co-led by Decheng Capital and Breton Capital, with part ...

2019-11-08 - Shape Therapeutics raises $35.5M Series A round to develop RNA-based gene editing technology

The company describes its technology, RNAfix, as allowing for direct in vivo targeting and modification of RNA by using engineered adeno-associated viruses, suppressor tRNAs and proteins like adenosine deaminases acting on RNA, or ADARs. ShapeTx further said that RNAfix differentiates from othe ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$69.1M17846%N/A
#2
$23.6M1797%N/A
#3
$15M1797%N/A
#4
$63.6M179N/AN/A
#5
$7.5M179-10%N/A